Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Core Insights - Sutro Biopharma, Inc. has regained compliance with Nasdaq's minimum share price requirement following a reverse stock split [1][2] Company Overview - Sutro Biopharma is a clinical-stage oncology company focused on developing site-specific and novel-format antibody drug conjugates (ADCs) [1][3] - The company aims to deliver single- and dual-payload ADCs to improve drug exposure, reduce side effects, and expand treatable tumor types [3] - Sutro's pipeline targets large oncology markets with significant unmet needs for improved therapies [3] Compliance with Nasdaq - As of December 16, 2025, Sutro's common stock maintained an average closing share price of at least $1.00 after a 1:10 reverse stock split effective December 3, 2025 [2] - The company is no longer considered below the minimum bid price requirement under Nasdaq Rule 5450(a)(1) [2]